ZYDUSLIFE
532321Transcript Of The 31St Annual General Meeting
Transcript of the 31st Annual General Meeting
Zydus Lifesciences Ltd, formerly known as Cadila Healthcare Ltd, is a leading Indian pharmaceutical company engaged in the research, development, manufacturing, and marketing of a broad spectrum of pharmaceutical products globally. Headquartered in Ahmedabad, Gujarat, Zydus operates across both formulations and APIs, with significant presence in specialty, generics, wellness, and consumer healthcare segments. The company maintains a strong footprint in over 50 countries, serving regulated markets such as the US, Europe, and emerging regions in Asia, Africa, and Latin America.
Transcript Of The 31St Annual General Meeting
Transcript of the 31st Annual General Meeting
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH.
Incorporation Of A Wholly Owned Subsidiary In Gift City, Gandhinagar, Gujarat
Incorporation of a wholly owned subsidiary in Gift City, Gandhinagar, Gujarat
ESG Rating
ESG Rating
Disclosure Under SEBI (Prohibition Of Insider Trading) Regulations, 2015
Disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015
Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation
ESG Rating
ESG Rating
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus announces final approval from the USFDA for Ascorbic Acid Injection with 180-Days CGT exclusivity.
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of the post results earnings call held on August 11, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The management of the Company will meet the investors in Singapore and Hong Kong between August 24, 2026, to August 26, 2026, in the form of a Non-Deal Roadshow (NDR).
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Update on Investor Conference
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper cutting with regard to publication of unaudited financial results for the quarter ended on June 30, 2026, in Financial Express on August 12, 2026.
Shareholder Meeting / Postal Ballot-Outcome of AGM
Regulation 44(3) disclosure of AGM 2026
Announcement under Regulation 30 (LODR)-Change in Directorate
Change in Directors
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Scrutinizer''s report
Shareholder Meeting / Postal Ballot-Outcome of AGM
Outcome of AGM
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Link of the Investor Call held on August 11 2026
Reporting Of Violation Of Code Of Conduct Under SEBI (Prohibition Of Insider Trading) Regulations, 2015
Reporting of violation of Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations, 2015
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release
Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation
Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended On June 30, 2026
Unaudited financial results for the quarter ended on June 30, 2026
Unaudited Financial Results For The Quarter Ended On June 30, 2026
Unaudited financial results for the quarter ended on June 30, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus launches REVAHALE, India''s first once-daily nebulised LAMA for COPD.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The Company is going to participate in Motilal Oswal 22nd Annual Global Investor Conference, 2026 on August 18, 2026.
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus announces Final Approval from the USFDA for Indocyanine Green for Injection with 180-Days CGT exclusivity.
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of notice of loss of share certificate of the Company, published in the Financial Express English and Gujarati editions, both on August 4, 2026.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Conference
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Conference
Zydus Lifesciences Ltd
About
Zydus Lifesciences Ltd, formerly known as Cadila Healthcare Ltd, is a leading Indian pharmaceutical company engaged in the research, development, manufacturing, and marketing of a broad spectrum of pharmaceutical products globally. Headquartered in Ahmedabad, Gujarat, Zydus operates across both formulations and APIs, with significant presence in specialty, generics, wellness, and consumer healthcare segments. The company maintains a strong footprint in over 50 countries, serving regulated markets such as the US, Europe, and emerging regions in Asia, Africa, and Latin America.
Zydus Lifesciences is recognized for its robust research and innovation capabilities, with multiple manufacturing facilities accredited by major international regulators including the USFDA, EMA, and MHRA. The company's integrated healthcare approach encompasses prescription drugs, vaccines, biosimilars, animal health, and consumer wellness products, underpinned by investments in new technologies and global partnerships to address evolving medical needs.
Business Model & Strategy
Zydus Lifesciences derives revenue through the development, manufacturing, and distribution of branded and generic pharmaceuticals, active pharmaceutical ingredients (APIs), vaccines, and consumer healthcare products. The company follows a vertically integrated model, leveraging its own R&D, backward integration in APIs, and extensive global supply chain to ensure cost efficiency and regulatory compliance. Its earnings stream is diversified by both therapeutic area (including cardiology, diabetology, gastroenterology, oncology, and pain management) and geography, with the US and India as primary markets.
Strategically, Zydus emphasizes building its specialty and biologics portfolio, expanding in emerging markets, and leveraging digital transformation in healthcare. Growth vectors include new product launches, strategic in-licensing, leveraging partnerships for biosimilars and vaccines, and expanding capabilities in novel drug delivery and biosimilars. Focus on sustainability and cost optimization further supports its long-term growth trajectory.
Management Overview
11 MembersMr.Pankaj R. Patel
Non-Executive - Non Independent Director-Chairperson related to PromoterMr.Sharvil P. Patel
Executive Director-MDMr.Ganesh N. Nayak
Executive Director-MDMr.Mukesh M. Patel
Non-Executive - Non Independent DirectorMr.Apurva S. Diwanji
Non-Executive - Independent DirectorMr.Bhadresh K. Shah
Non-Executive - Independent DirectorMr.Akhil Monappa
Non-Executive - Independent DirectorMs.Upasana Konidela
Non-Executive - Independent DirectorMs.Shelina Parikh
Non-Executive - Independent DirectorMr.NitinDParekh
Chief Financial OfficerMr.DhavalN.Soni
Company Secretary & Compliance OfficerAwards & Recognition
5 Awards- Awarded the 'India Pharma Leader of the Year' at the India Pharma Awards 2024
- Ranked among India's Top 20 Best Workplaces in Health & Wellness (Great Place to Work, 2024)
- Included in S&P Global’s Sustainability Yearbook 2024
- Recipient of USFDA approvals for several manufacturing facilities in 2023 and 2024
- Recognized in Fortune India's 'Most Admired Companies' list, 2024
Market Information
Company Timeline
73+ Years of Excellence | 11 Major Milestones
Company founded as Cadila Laboratories by Ramanbhai Patel
Formation of Cadila Healthcare Ltd following demerger
Initial Public Offering (IPO) and listing on BSE & NSE
Foray into regulated US generics market
Acquisition of Biochem, strengthening domestic presence
Launch of India's first biosimilar of Adalimumab (Exemptia)
Establishment of Zydus Wellness through merger and expansion of consumer division
Emergency use approval for ZyCoV-D, world's first DNA-based COVID-19 vaccine
Company rebrands as Zydus Lifesciences Ltd, reflecting broader healthcare focus
Multiple launches in specialty and biosimilars for US and Europe markets
Further expansion in global oncology and complex generics portfolio
The Next Evolution
Contact Information
Registered Office
Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Sarkhej - Gandhinagar Highway, Nr. Vaishnodevi Circle
Tel: 079-26868100,
Fax: 079-26868337, 26862365, 26862366,
Email: dhavalsoni@zyduscadila.com; upen.shah@zyduscadila.com; investor.grievance@zyduscadila.com
Website: zyduslife.com
Corporate Actions
16| Purpose | Ex Date | Record Date | BC Start | BC End |
|---|---|---|---|---|
Final Dividend ₹1 per share | 24 Jul 2026 Friday | 24 Jul 2026 Friday | - | - |
Buy Back of Shares | 29 May 2026 Friday | 29 May 2026 Friday | - | - |
Final Dividend ₹11 per share | 25 Jul 2025 Friday | 25 Jul 2025 Friday | - | - |
Final Dividend ₹3 per share | 26 Jul 2024 Friday | 26 Jul 2024 Friday | - | - |
Buy Back of Shares | 23 Feb 2024 Friday | 23 Feb 2024 Friday | - | - |
Final Dividend ₹6 per share | 28 Jul 2023 Friday | 28 Jul 2023 Friday | - | - |
Final Dividend ₹2.50 per share | 28 Jul 2022 Thursday | 29 Jul 2022 Friday | - | - |
Buy Back of Shares | 01 Jun 2022 Wednesday | 02 Jun 2022 Thursday | - | - |
Final Dividend ₹3.50 per share | 28 Jul 2021 Wednesday | - | 30 Jul 2021 Friday | 06 Aug 2021 Friday |
Interim Dividend ₹3.50 per share | 23 Mar 2020 Monday | 24 Mar 2020 Tuesday | - | - |
Final Dividend ₹3.50 per share | 25 Jul 2019 Thursday | - | 29 Jul 2019 Monday | 09 Aug 2019 Friday |
Dividend ₹3.50 per share | 31 Jul 2018 Tuesday | - | 02 Aug 2018 Thursday | 13 Aug 2018 Monday |
Interim Dividend ₹3.20 per share | 16 Mar 2017 Thursday | 17 Mar 2017 Friday | - | - |
Interim Dividend ₹3.20 per share | 17 Mar 2016 Thursday | 18 Mar 2016 Friday | - | - |
Stock Split From Rs.5/- to Rs.1/- | 06 Oct 2015 Tuesday | 07 Oct 2015 Wednesday | - | - |
Dividend ₹12 per share | 30 Jul 2015 Thursday | - | 03 Aug 2015 Monday | 12 Aug 2015 Wednesday |
₹1,16,409 Cr.
₹1,164
₹1,205 / 836
26.03
₹296.56
3.94
₹44.87
₹1.00
0.09 %
Manage Ratio
FINANCIALS
| Annual Results | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | - | - | - | 13,367 | 14,367 | 15,139 | 15,490 | 17,424 | 19,832 | 23,511 | 27,658 | 29,052 |
| Expenses | - | - | - | 10,985 | 12,508 | 12,650 | 12,765 | 14,230 | 15,008 | 17,265 | 20,520 | 22,511 |
| Profit | - | - | - | 1,899 | 1,204 | 2,185 | 4,618 | 2,092 | 3,973 | 4,673 | 5,124 | 4,593 |
| Tax | - | - | - | 530 | 320 | 147 | 512 | 588 | 978 | 1,412 | 1,595 | 1,515 |
| EPS | - | - | - | 18 | 11 | 21 | 22 | 19 | 38 | 45 | 50 | 9.35 |
| Ratios | - |
Cash Flow
Consolidated Figures in Rs. Crores
| Annual Balance Sheet | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | - | - | - | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 | 37,202 | 52,407 | - |
| Equity And Liabilities | - | - | - | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 | 37,202 | 52,407 | - |
Shareholding Pattern
Numbers in Percentages
| Quarterly SHP Announcement Date | Mar 2016 12 Apr '16 | Mar 2017 31 Mar '17 | Mar 2018 31 Mar '18 | Mar 2019 12 Apr '19 | Mar 2020 20 Apr '20 | Mar 2021 08 Apr '21 | Mar 2022 07 Apr '22 | Mar 2023 08 Apr '23 | Mar 2024 09 Apr '24 | Mar 2025 12 Apr '25 | Mar 2026 31 Mar '26 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goverments | - | - | - | 0.13% | 0.14% | 0.19% | 0.08% | - | - | - | - | - |
| Promoter And Promoter Group | - | - | - | 74.79% | 74.88% | 74.88% | 74.88% | 74.98% | 74.98% | 74.99% | - | - |
| Non Institutions | - | - | - | 7.90% | 7.67% | 8.40% | 9.69% | 8.00% | 6.66% | 6.68% | - | - |
| FII | - | - | - | - | - | - | - | 3.42% | 5.72% | 7.32% | - | - |
| DII | - | - | - | - | - | - | - | 13.60% | 12.63% | 11.01% | - | - |
| Total | - | - | - | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - | - |
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd, formerly known as Cadila Healthcare Ltd, is a leading Indian pharmaceutical company engaged in the research, development, manufacturing, and marketing of a broad spectrum of pharmaceutical products globally. Headquartered in Ahmedabad, Gujarat, Zydus operates across both formulations and APIs, with significant presence in specialty, generics, wellness, and consumer healthcare segments. The company maintains a strong footprint in over 50 countries, serving regulated markets such as the US, Europe, and emerging regions in Asia, Africa, and Latin America.
Zydus Lifesciences is recognized for its robust research and innovation capabilities, with multiple manufacturing facilities accredited by major international regulators including the USFDA, EMA, and MHRA. The company's integrated healthcare approach encompasses prescription drugs, vaccines, biosimilars, animal health, and consumer wellness products, underpinned by investments in new technologies and global partnerships to address evolving medical needs.
Zydus Lifesciences derives revenue through the development, manufacturing, and distribution of branded and generic pharmaceuticals, active pharmaceutical ingredients (APIs), vaccines, and consumer healthcare products. The company follows a vertically integrated model, leveraging its own R&D, backward integration in APIs, and extensive global supply chain to ensure cost efficiency and regulatory compliance. Its earnings stream is diversified by both therapeutic area (including cardiology, diabetology, gastroenterology, oncology, and pain management) and geography, with the US and India as primary markets.
Strategically, Zydus emphasizes building its specialty and biologics portfolio, expanding in emerging markets, and leveraging digital transformation in healthcare. Growth vectors include new product launches, strategic in-licensing, leveraging partnerships for biosimilars and vaccines, and expanding capabilities in novel drug delivery and biosimilars. Focus on sustainability and cost optimization further supports its long-term growth trajectory.
Awarded the 'India Pharma Leader of the Year' at the India Pharma Awards 2024
Ranked among India's Top 20 Best Workplaces in Health & Wellness (Great Place to Work, 2024)
Included in S&P Global’s Sustainability Yearbook 2024
Recipient of USFDA approvals for several manufacturing facilities in 2023 and 2024
Recognized in Fortune India's 'Most Admired Companies' list, 2024
Company founded as Cadila Laboratories by Ramanbhai Patel
Formation of Cadila Healthcare Ltd following demerger
Initial Public Offering (IPO) and listing on BSE & NSE
Foray into regulated US generics market
Acquisition of Biochem, strengthening domestic presence
Launch of India's first biosimilar of Adalimumab (Exemptia)
Establishment of Zydus Wellness through merger and expansion of consumer division
Emergency use approval for ZyCoV-D, world's first DNA-based COVID-19 vaccine
Company rebrands as Zydus Lifesciences Ltd, reflecting broader healthcare focus
Multiple launches in specialty and biosimilars for US and Europe markets
Further expansion in global oncology and complex generics portfolio
Peer Comparison
| S.No. | Company Name | CMP (₹) | Market Cap (₹ Cr) | Div Yld (%) | NP Qtr (₹ Cr) | Qtr Profit Var (%) | Sales Qtr (₹ Cr) | Qtr Sales Var (%) | ROCE (%) | ROE (%) | Book Value (₹) | EPS TTM (₹) | TTMPE Ratio (₹) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon
Heatmap View
Premium Feature| Company | CMP (₹) | MCap (₹ Cr) | EPS TTM (₹) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Financial Ratios
Premium Feature| Company Name | P/E (TTM) | EPS (₹) | D/E | NPM | GPM | ROE (%) | ROCE (%) | P/B | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon